Addendum

Pembrolizumab (urothelial cancer, first line treatment, combination with enfortumab vedotin) – Addendum to Project A24-99

Report documents

Indication:

First-line treatment of adult patients with unresectable or metastatic urothelial carcinoma

Result of dossier assessment:

unchanged after addendum:

Patients for whom cisplatin-based therapy is a suitable treatment option: hint of non-quantifiable added benefit
Patients for whom cisplatin-based therapy is not a suitable treatment option: hint of major added benefit
Patients for whom cisplatin-based and carboplatin-based therapy is not a suitable treatment option: added benefit not proven

2025-04-03 A G-BA decision was published.

Project no.: A25-23
Commission: Commission awarded on 11.02.2025 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI: https://doi.org/10.60584/A25-23_en

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.